|
1
|
Nishida N, Yano H, Nishida T, Kamura T and
Kojiro M: Angiogenesis in cancer. Vasc Health Risk Manag.
2:213–219. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Schneider BP and Miller KD: Angiogenesis
of breast cancer. J Clin Oncol. 23:1782–1790. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
LeCouter J, Lin R and Ferrara N: The role
of EG-VEGF in the regulation of angiogenesis in endocrine glands.
Cold Spring Harb Symp Quant Biol. 67:217–221. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kaser A, Winklmayr M, Lepperdinger G and
Kreil G: The AVIT protein family. Secreted cysteine-rich vertebrate
proteins with diverse functions. EMBO Rep. 4:469–473. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhou QY and Meidan R: Biological function
of prokineticins. Results Probl Cell Differ. 46:181–199. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Keramidas M, Faudot C, Cibiel A, Feige JJ
and Thomas M: Mitogenic functions of endocrine gland-derived
vascular endothelial growth factor and Bombina variegata 8 on
steroidogenic adrenocortical cells. J Endocrinol. 196:473–482.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kisliouk T, Levy N, Hurwitz A and Meidan
R: Presence and regulation of endocrine gland vascular endothelial
growth factor/prokineticin-1 and its receptors in ovarian cells. J
Clin Endocrinol Metab. 88:3700–3707. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fraser HM, Bell J, Wilson H, Taylor PD,
Morgan K, Anderson RA and Duncan WC: Localization and
quantification of cyclic changes in the expression of endocrine
gland vascular endothelial growth factor in the human corpus
luteum. J Clin Endocrinol Metab. 90:427–434. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Morales A, Morimoto S, Díaz L, Robles G
and Díaz-Sánchez V: Endocrine gland-derived vascular endothelial
growth factor in rat pancreas: Genetic expression and testosterone
regulation. J Endocrinol. 197:309–314. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nagano H, Goi T, Koneri K, Hirono Y,
Katayama K and Yamaguchi A: Endocrine gland-derived vascular
endothelial growth factor (EG-VEGF) expression in colorectal
cancer. J Surg Oncol. 96:605–610. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
PerrotApplanat M and Di Benedetto M:
Autocrine functions of VEGF in breast tumor cells: Adhesion,
survival, migration and invasion. Cell Adh Migr. 6:547–553. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kassim SK, ElSalahy EM, Fayed ST, Helal
SA, Helal T, Azzam Eel-D and Khalifa A: Vascular endothelial growth
factor and interleukin-8 are associated with poor prognosis in
epithelial ovarian cancer patients. Clin Biochem. 37:363–369. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
DeSantis CE, Bray F, Ferlay J,
LortetTieulent J, Anderson BO and Jemal A: International variation
in female breast cancer incidence and mortality rates. Cancer
Epidemiol Biomarkers Prev. 24:1495–1506. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Córdova JA, Hernández M, Ortiz ME, Lezana
MA, López-Gatell H and Alpuche CM: Epidemiological profile of
malignant tumors in Mexico. In: IEPSA. Mexico City. pp. 145–195.
2011;
|
|
15
|
Euhus D, Di Carlo PA and Khouri NF: Breast
cancer screening. Surg Clin North Am. 95:991–1011. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kennecke H, Yerushalmi R, Woods R, Cheang
MC, Voduc D, Speers CH, Nielsen TO and Gelmon K: Metastatic
behavior of breast cancer subtypes. J Clin Oncol. 28:3271–3277.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li J, Chen Z, Su K and Zeng J:
Clinicopathological classification and traditional prognostic
indicators of breast cancer. Int J Clin Exp Pathol. 8:8500–8505.
2015.PubMed/NCBI
|
|
18
|
Mao Q and Unadkat JD: Role of the breast
cancer resistance protein (BCRP/ABCG2) in drug transport-an update.
AAPS J. 17:65–82. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Faneyte IF, Kristel PM, Maliepaard M,
Scheffer GL, Scheper RJ, Schellens JH and van de Vijver MJ:
Expression of the breast cancer resistance protein in breast
cancer. Clin Cancer Res. 8:1068–1074. 2002.PubMed/NCBI
|
|
20
|
Glavinas H, Krajcsi P, Cserepes J and
Sarkadi B: The role of ABC transporters in drug resistance,
metabolism and toxicity. Curr Drug Deliv. 1:27–42. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Javam M, Audette MC, Iqbal M, Bloise E,
Gibb W and Matthews SG: Effect of oxygen on multidrug resistance in
term human placenta. Placenta. 35:324–330. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Vore M and Leggas M: Progesterone acts via
progesterone receptors A and B to regulate breast cancer resistance
protein expression. Mol Pharmacol. 73:613–615. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang Y, Wang H, Wei L, Li G, Yu J, Gao Y,
Gao P, Zhang X, Wei F, Yin D and Zhou G: Transcriptional modulation
of BCRP gene to reverse multidrug resistance by toremifene in
breast adenocarcinoma cells. Breast Cancer Res Treat. 123:679–689.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Diestra JE, Scheffer GL, Catala I,
Maliepaard M, Schellens JH, Scheper RJ, Germà-Lluch JR and
Izquierdo MA: Frequent expression of the multi-drug
resistance-associated protein BCRP/MXR/ABCP/ABCG2 in human tumours
detected by the BXP-21 monoclonal antibody in paraffin-embedded
material. J Pathol. 198:213–219. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang H, Lee EW, Zhou L, Leung PC, Ross DD,
Unadkat JD and Mao Q: Progesterone receptor (PR) isoforms PRA and
PRB differentially regulate expression of the breast cancer
resistance protein in human placental choriocarcinoma BeWo cells.
Mol Pharmacol. 73:845–854. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Nakagawa M, Schneider E, Dixon KH, Horton
J, Kelley K, Morrow C and Cowan KH: Reduced intracellular drug
accumulation in the absence of P-glycoprotein (mdr1) overexpression
in mitoxantrone-resistant human MCF-7 breast cancer cells. Cancer
Res. 52:6175–6181. 1992.PubMed/NCBI
|
|
27
|
Schumacher M, Schmoor C, Sauerbrei W,
Schauer A, Ummenhofer L, Gatzemeier W and Rauschecker H: The
prognostic effect of histological tumor grade in node-negative
breast cancer patients. Breast Cancer Res Treat. 25:235–245. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
PanchukVoloshina N and Haugland RP,
BishopStewart J, Bhalgat MK, Millard PJ, Mao F, Leung WY and
Haugland RP: Alexa dyes, a series of new fluorescent dyes that
yield exceptionally bright, photostable conjugates. J Histochem
Cytochem. 47:1179–1188. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chu P, Wu E and Weiss LM: Cytokeratin 7
and cytokeratin 20 expression in epithelial neoplasms: A survey of
435 cases. Mod Pathol. 13:962–972. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Santagata S, Thakkar A, Ergonul A, Wang B,
Woo T, Hu R, Harrell JC, McNamara G, Schwede M, Culhane AC, et al:
Taxonomy of breast cancer based on normal cell phenotype predicts
outcome. J Clin Invest. 124:859–870. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Howlett AR and Bissell MJ: The influence
of tissue microenvironment (stroma and extracellular matrix) on the
development and function of mammary epithelium. Epithelial Cell
Biol. 2:79–89. 1993.PubMed/NCBI
|
|
32
|
Obr AE and Edwards DP: The biology of
progesterone receptor in the normal mammary gland and in breast
cancer. Mol Cell Endocrinol. 357:4–17. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Shak S: Overview of the trastuzumab
(Herceptin) anti-HER2 monoclonal antibody clinical program in
HER2-overexpressing metastatic breast cancer. Herceptin
Multinational Investigator Study Group. Semin Oncol. 26(Suppl 12):
71–77. 1999.PubMed/NCBI
|
|
34
|
Schmadeka R, Harmon BE and Singh M:
Triple-negative breast carcinoma: Current and emerging concepts. Am
J Clin Pathol. 141:462–477. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Perou CM, Sørlie T, Eisen MB, van de Rijn
M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA,
et al: Molecular portraits of human breast tumors. Nature.
406:747–752. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
36
|
Bauer KR, Brown M, Cress RD, Parise CA and
Caggiano V: Descriptive analysis of estrogen receptor
(ER)-negative, progesterone receptor (PR)-negative and
HER2-negative invasive breast cancer, the so-called triple-negative
phenotype: A population-based study from the California cancer
registry. Cancer. 109:1721–1728. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Linderholm BK, Hellborg H, Johansson U,
Elmberger G, Skoog L, Lehtiö J and Lewensohn R: Significantly
higher levels of vascular endothelial growth factor (VEGF) and
shorter survival times for patients with primary operable
triple-negative breast cancer. Ann Oncol. 20:1639–1646. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
LeCouter J, Kowalski J, Foster J, Hass P,
Zhang Z, DillardTelm L, Frantz G, Rangell L, DeGuzman L, Keller GA,
et al: Identification of an angiogenic mitogen selective for
endocrine gland endothelium. Nature. 412:877–884. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Moitra K, Lou H and Dean M: Multidrug
efflux pumps and cancer stem cells: Insights into multidrug
resistance and therapeutic development. Clin Pharmacol Ther.
89:491–502. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Dankers AC, Sweep FC, Pertijs JC, Verweij
V, van den Heuvel JJ, Koenderink JB, Russel FG and Masereeuw R:
Localization of breast cancer resistance protein (Bcrp) in
endocrine organs and inhibition of its transport activity by
steroid hormones. Cell Tissue Res. 349:551–563. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ee PL, Kamalakaran S, Tonetti D, He X,
Ross DD and Beck WT: Identification of a novel estrogen response
element in the breast cancer resistance protein (ABCG2) gene.
Cancer Res. 64:1247–1251. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Imai Y, Ishikawa E, Asada S and Sugimoto
Y: Estrogen-mediated post transcriptional down-regulation of breast
cancer resistance protein/ABCG2. Cancer Res. 65:596–604.
2005.PubMed/NCBI
|
|
43
|
Roy S, Gascard P, Dumont N, Zhao J, Pan D,
Petrie S, Margeta M and Tlsty TD: Rare somatic cells from human
breast tissue exhibit extensive lineage plasticity. Proc Natl Acad
Sci USA. 110:4598–4603. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Dempke WC and Heinemann V: Resistance to
EGF-R (erbB-1) and VEGF-R modulating agents. Eur J Cancer.
45:1117–1128. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Mercurio AM, Lipscomb EA and Bachelder RE:
Non-angiogenic functions of VEGF in breast cancer. J Mammary Gland
Biol Neoplasia. 10:283–290. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Bergers G and Hanahan D: Modes of
resistance to anti-angiogenic therapy. Nat Rev Cancer. 8:592–603.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Chan A: Antiangiogenic therapy for
metastatic breast cancer: current status and future directions.
Drugs. 69:167–181. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
BanysPaluchowski M, Schütz F, Ruckhäberle
E, Krawczyk N and Fehm T: Metronomic chemotherapy for metastatic
breast cancer - a systematic review of the literature. Geburtshilfe
Frauenheilkd. 76:525–534. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Ruohola JK, Valve EM, Karkkainen MJ,
Joukov V, Alitalo K and Härkönen PL: Vascular endothelial growth
factors are differentially regulated by steroid hormones and
antiestrogens in breast cancer cells. Mol Cell Endocrinol.
149:29–40. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Takei H, Lee ES and Jordan VC: In vitro
regulation of vascular endothelial growth factor by estrogens and
antiestrogens in estrogen-receptor positive breast cancer. Breast
Cancer. 9:39–42. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Bogin L and Degani H: Hormonal regulation
of VEGF in orthotopic MCF7 human breast cancer. Cancer Res.
62:1948–1951. 2002.PubMed/NCBI
|
|
52
|
Mirkin S, Wong BC and Archer DF: Effect of
17 beta-estradiol, progesterone, synthetic progestins, tibolone and
tibolone metabolites on vascular endothelial growth factor mRNA in
breast cancer cells. Fertil Steril. 84:485–491. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Mirkin S, Wong BC and Archer DF: Effects
of 17beta-estradiol, progesterone, synthetic progestins, tibolone
and raloxifene on vascular endothelial growth factor and
Thrombospondin-1 messenger RNA in breast cancer cells. Int J
Gynecol Cancer. 16(Suppl 2): S560–S563. 2006. View Article : Google Scholar
|
